Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126

Arthritis and Rheumatism

Volumn 64, Issue 11, 2012, Pages 3809-3817

  Kim, Erin ^a   Cook Mills, Joan ^a   Morgan, Gabrielle ^a   Sredni, Simone T ^a   Pachman, Lauren M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; MICRORNA 126; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; JUVENILE DERMATOMYOSITIS; MALE; MUSCLE BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

BIOPSY; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; FEMALE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICRORNAS; MUSCLE, SKELETAL; TRANSCRIPTOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84868103669     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34606     Document Type: Article

References (43)

1. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al, for the NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49: 300-5.
2. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
3. Banker BQ, Victor M,. Dermatomyositis (systemic angiopathy) of childhood. Medicine (Baltimore) 1966; 45: 261-89.
4. Carpenter S, Karpati G, Rothman S, Watters G,. The childhood type of dermatomyositis. Neurology 1976; 26: 952-62.
5. Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM,. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58: 571-6.
6. Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM,. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31: 1644-9.
7. Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM,. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 59: 222-6.
8. Nagaraju K, Rider LG, Fan C, Chen YW, Mitsak M, Rawat R, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 2006; 3: 2.
9. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006; 148: 247-53.
10. Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, et al. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum 2007; 56: 977-83.
11. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436-46.
12. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002; 168: 4154-63.
13. Chen YW, Shi R, Geraci N, Shrestha S, Gordish-Dressman H, Pachman LM,. Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol 2008; 9: 43.
14. De Visser M, Emslie-Smith AM, Engel AG,. Early ultrastructural alterations in adult dermatomyositis: capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989; 94: 181-92.
15. Cid MC, Grau JM, Casademont J, Tobias E, Picazo A, Coll-Vinent B, et al. Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM). Clin Exp Immunol 1996; 104: 467-73.
16. Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF,. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003; 28: 659-82.
17. Jain A, Sharma MC, Sarkar C, Bhatia R, Singh S, Handa R,. Increased expression of cell adhesion molecules in inflammatory myopathies: diagnostic utility and pathogenetic insights. Folia Neuropathol 2009; 47: 33-42.
18. Sallum AM, Marie SK, Wakamatsu A, Sachetti S, Vianna MA, Silva CA, et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol 2004; 31: 801-7.
19. Sallum AM, Kiss MH, Silva CA, Wakamatsu A, Vianna MA, Sachetti S, et al. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev 2006; 5: 93-100.
20. Tews DS, Goebel HH,. Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol 1995; 59: 185-94.
21. Iademarco MF, McQuillan JJ, Dean DC,. Vascular cell adhesion molecule 1: contrasting transcriptional control mechanisms in muscle and endothelium. Proc Natl Acad Sci U S A 1993; 90: 3943-7.
22. Rosen GD, Sanes JR, LaChance R, Cunningham JM, Roman J, Dean DC,. Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis. Cell 1992; 69: 1107-19.
23. Von Andrian UH, Engelhardt B,. α4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68-72.
24. McMurray RW,. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 1996; 25: 215-33.
25. Lebranchu Y, Valentin JF, Buchler M,. Measurement of soluble adhesion molecules in biological fluids. In:, Paul LC, Issekutz TB, editors. Adhesion molecules in health and disease. New York: Marcel Dekker; 1997. p. 87-122.
26. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNFα-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43: 2368-77.
27. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107: 1255-62.
28. Budhu A, Ji J, Wang XW,. The clinical potential of microRNAs. J Hematol Oncol 2010; 3: 37.
29. Doench JG, Sharp PA,. Specificity of microRNA target selection in translational repression. Genes Dev 2004; 18: 504-11.
30. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL,. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 1997; 36: 164-9.
31. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG,. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE): a long term prospective study. Clin Exp Immunol 1994; 97: 439-44.
32. Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, et al. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. J Am Acad Dermatol 2000; 42: 64-9.
33. Bloom BJ, Miller LC, Blier PR,. Soluble adhesion molecules in pediatric rheumatic diseases. J Rheumatol 2002; 29: 832-6.
34. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
35. Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ,. The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010; 185: 4457-69.
36. Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: a biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994; 37: 1744-51.
37. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ,. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105: 1516-21.
38. Charreau B,. Molecular regulation of endothelial cell activation: novel mechanisms and emerging targets. Curr Opin Organ Transplant 2011; 16: 207-13.
39. Urbich C, Kuehbacher A, Dimmeler S,. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008; 79: 581-8.
40. Bai Y, Bai X, Wang Z, Zhang X, Ruan C, Miao J,. MicroRNA-126 inhibits ischemia-induced retinal neovascularization via regulating angiogenic growth factors. Exp Mol Pathol 2011; 91: 471-7.
41. Ryu HS, Park SY, Ma D, Zhang J, Lee W,. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS One 2011; 6: e17343.
42. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008; 87: 70-86.
43. Eimer MJ, Brickman WJ, Seshadri R, Ramsey-Goldman R, McPherson DD, Smulevitz B, et al. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. J Pediatr 2011; 159: 795-801.